The emergence of antibiotic resistant bacteria is one of the greatest threats to human health in the 21st century. Among these bacteria, vancomycin-resistant enterococci (VRE) are one of the most challenging organisms in clinical settings. Indeed, vancomycin-resistant Enterococcus faecium have been designated by the Infectious Disease Society of America as one of the superbugs against which new therapies are urgently needed. Currently, one of the antibiotics with in vitro bactericidal against VRE is daptomycin (DAP), a lipopeptide antibiotic that has become the key front-line antimicrobial against these organisms due to the paucity of other options. However, the main challenge when using DAP against VRE is the development of resistance during therapy. We have identified a cluster of genes in enterococci (designated liaFSR), encoding a three- component regulatory system likely involved in the cell envelope bacterial response to antibiotics which is highly conserved in Gram-positive pathogens. Our preliminary data indicate that LiaR (encoding the response regulator of the system) is the master regulator of antibiotic resistance in DAP-resistant VRE since deletion of the gene reversed resistance to DAP in several strains of E. faecalis and E. faecium, independent of the genetic background. Therefore, we hypothesize that inhibition of the LiaR response would disarm VRE by altering the bacterial adaptive response to the attack by antimicrobials. In this proposal we seek to develop a new class of molecules (designated anti-adaptation antibiotics) by developing molecules that inhibit LiaR. These compounds are expected to act synergistically with other antibiotics (e.g., DAP) and prevent emergence of resistance. We will develop our experimental approach in two phases. In the R21 phase, the Specific Aims include, i) characterization of the role of LiaR in vancomycin-resistant E. faecium by generating additional liaR gene knockouts from E. faecium, select in vitro DAP-resistant mutants in a liaR deletion mutant, and investigate the liaR regulon as well as developing biochemical tests to evaluate its activity and obtain structural data as the basis for structure-activity relationship studies, and ii) develop a high throughput strategy to identify compounds that are likely to inhibit LiaR activity using reversion of DAP susceptibility as a surrogate marke. The screening will be performed using compound libraries present at research sites associated with this application. Compounds identified would be tested for their ability to interact with LiaR using biochemical and structural data developed in Sp Aim (i). In the R33 phase, we will seek to i) optimize the chemical development of LiaR inhibitors by improving the properties of the hit compounds based on the biochemical and structural information generated in the R21 phase, and ii) assess the in vivo toxicity and efficacy of novel compounds by performing proof of principle in vivo studies using a mouse peritonitis model with calculation of the maximal tolerated dose in animals. At the end of this proposal, we expect to deliver novel compounds that could be used as anti-adaptation antibiotics for further clinical development.

Public Health Relevance

Antibiotic resistance is a major public-health threat of the 21st century that is highlighted by the Centers for Dis- ease Control and Prevention. Vancomycin-resistant enterococci (VRE) are considered as one of the most important hospital-associated organisms affecting critically ill patients. Treatment of VRE infections poses immense therapeutic dilemmas in clinical settings due to the lack of reliable antibiotic options, making these infections untreatable in certain scenarios. This proposal seeks to develop a novel class of molecules (designated 'anti-adaptation' antibiotics) by developing molecules that inhibit LiaR, the 'master' response regulator of the cell envelope response to the antimicrobial attack in VRE and other clinically relevant Gram-positive bacteria. This novel strategy seeks to restore the activity of current anti-VRE antibiotics and prevent development of resistance, a novel approach against multidrug-resistant organisms.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI121519-02
Application #
9197605
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Xu, Zuoyu
Project Start
2015-12-18
Project End
2017-11-30
Budget Start
2016-12-01
Budget End
2017-11-30
Support Year
2
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Texas Health Science Center Houston
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225
Davlieva, Milya; Tovar-Yanez, Angel; DeBruler, Kimberly et al. (2016) An Adaptive Mutation in Enterococcus faecium LiaR Associated with Antimicrobial Peptide Resistance Mimics Phosphorylation and Stabilizes LiaR in an Activated State. J Mol Biol 428:4503-4519
Tran, Truc T; Miller, William R; Shamoo, Yousif et al. (2016) Targeting cell membrane adaptation as a novel antimicrobial strategy. Curr Opin Microbiol 33:91-96
Planet, Paul J; Diaz, Lorena; Rios, Rafael et al. (2016) Global Spread of the Community-Associated Methicillin-Resistant Staphylococcus aureus USA300 Latin American Variant. J Infect Dis 214:1609-1610
Harp, John R; Saito, Holly E; Bourdon, Allen K et al. (2016) Exogenous Fatty Acids Protect Enterococcus faecalis from Daptomycin-Induced Membrane Stress Independently of the Response Regulator LiaR. Appl Environ Microbiol 82:4410-20